Skip to main content
. 2019 May 11;8(7):460–468. doi: 10.1002/psp4.12405

Table 1.

Overview of simulation scenarios

Study design Doses Number of participants Slope No. of scenarios
SAD (4 periods/participants) 0, 2.4, 4.0, 4.8 mg 12, 24, 36, 48 Zero, intermediate, high 12
MAD (parallel) 0, 1.2, 2.0, 2.4 mg twice daily 12, 24, 36, 48 Zero, intermediate, high 12
SAD/MAD As above 12/36, 24/24, 36/12 Zero, intermediate, high 9

MAD, multiple‐ascending dose; SAD, single‐ascending dose.